Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

70 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of intravenous ciprofloxacin in patients with febrile neutropenia refractory to initial therapy.
Matsuoka H, Tsukamoto A, Shirahashi A, Koga S, Suzushima H, Shibata K, Uozumi K, Yamashita K, Okamura S, Kawano F, Tamura K; Kyushu Hematology Organization for Treatment (K-HOT) Study Group, Fukuoka, Japan. Matsuoka H, et al. Among authors: suzushima h. Leuk Lymphoma. 2006 Aug;47(8):1618-23. doi: 10.1080/10428190600572731. Leuk Lymphoma. 2006. PMID: 16966275 Clinical Trial.
Phase I study of the combination of irinotecan hydrochloride, carboplatin, and dexamethasone for the treatment of relapsed or refractory malignant lymphoma.
Suzumiya J, Suzushima H, Maeda K, Okamura S, Utsunomiya A, Shibuya T, Tamura K; Kyushu Hematology Organization for Treatment Study Group. Suzumiya J, et al. Among authors: suzushima h. Int J Hematol. 2004 Apr;79(3):266-70. doi: 10.1532/ijh97.03071. Int J Hematol. 2004. PMID: 15168596 Clinical Trial.
THP-COP regimen for the treatment of peripheral T-cell lymphoma and adult T-cell leukemia/lymphoma: a multicenter phase II study.
Takamatsu Y, Suzumiya J, Utsunomiya A, Maeda K, Matsuoka H, Suzushima H, Tsukada J, Shibata K, Tamura K; Kyushu Hematology Organization for Treatment Study Group (K-HOT). Takamatsu Y, et al. Among authors: suzushima h. Eur J Haematol. 2010 May;84(5):391-7. doi: 10.1111/j.1600-0609.2010.01411.x. Epub 2010 Jan 5. Eur J Haematol. 2010. PMID: 20059527 Clinical Trial.
Treatment and survival among 1594 patients with ATL.
Katsuya H, Ishitsuka K, Utsunomiya A, Hanada S, Eto T, Moriuchi Y, Saburi Y, Miyahara M, Sueoka E, Uike N, Yoshida S, Yamashita K, Tsukasaki K, Suzushima H, Ohno Y, Matsuoka H, Jo T, Amano M, Hino R, Shimokawa M, Kawai K, Suzumiya J, Tamura K; ATL-Prognostic Index Project. Katsuya H, et al. Among authors: suzushima h. Blood. 2015 Dec 10;126(24):2570-7. doi: 10.1182/blood-2015-03-632489. Epub 2015 Sep 11. Blood. 2015. PMID: 26361794 Free article.
Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in Japan: a retrospective analysis of 1,057 cases from Kyushu Lymphoma Study Group.
Seki R, Ohshima K, Nagafuji K, Fujisaki T, Uike N, Kawano F, Gondo H, Makino S, Eto T, Moriuchi Y, Taguchi F, Kamimura T, Tsuda H, Ogawa R, Shimoda K, Yamashita K, Suzuki K, Suzushima H, Tsukazaki K, Higuchi M, Utsunomiya A, Iwahashi M, Imamura Y, Tamura K, Suzumiya J, Yoshida M, Abe Y, Matsumoto T, Okamura T. Seki R, et al. Among authors: suzushima h. Int J Hematol. 2010 Mar;91(2):258-66. doi: 10.1007/s12185-009-0475-2. Int J Hematol. 2010. PMID: 20066574
Prognostic impact of immunohistochemical biomarkers in diffuse large B-cell lymphoma in the rituximab era.
Seki R, Ohshima K, Fujisaki T, Uike N, Kawano F, Gondo H, Makino S, Eto T, Moriuchi Y, Taguchi F, Kamimura T, Tsuda H, Ogawa R, Shimoda K, Yamashita K, Suzuki K, Suzushima H, Tsukazaki K, Higuchi M, Utsunomiya A, Iwahashi M, Imamura Y, Tamura K, Suzumiya J, Yoshida M, Abe Y, Matsumoto T, Okamura T. Seki R, et al. Among authors: suzushima h. Cancer Sci. 2009 Oct;100(10):1842-7. doi: 10.1111/j.1349-7006.2009.01268.x. Epub 2009 Jul 1. Cancer Sci. 2009. PMID: 19656156 Free PMC article.
70 results